BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Sridharan M, Kluge ML, Go RS, Abraham RS, Moyer AM. Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100002. [DOI: 10.1016/j.tru.2020.100002] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
3 Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020;12:295-305. [PMID: 32210633 DOI: 10.2147/clep.s245642] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
4 Sarada Nandiwada L, Ntrivalas E, O'Gorman MRG. Updates in diagnostic and clinical laboratory immunology from the 30th annual meeting of the Association of Medical Laboratory Immunologists (AMLI). J Immunol Methods 2019;464:138-40. [PMID: 30452901 DOI: 10.1016/j.jim.2018.11.007] [Reference Citation Analysis]
5 Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E919. [PMID: 31252541 DOI: 10.3390/jcm8070919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Naranjo Muñoz J, Garcia Garcia-doncel A, Montero Escobar ME, Villanego Fernandez F, Millán Ortega I, Ceballos Guerrero M. Eculizumab en el síndrome hemolítico urémico atípico. ¿Hasta cuándo mantenerlo? Nefrología 2019;39:440-2. [DOI: 10.1016/j.nefro.2019.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sridharan M, Hook CC, Leung N, Winters JL, Go RS; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Postsurgical thrombotic microangiopathy: Case series and review of the literature. Eur J Haematol 2019;103:307-18. [PMID: 31251415 DOI: 10.1111/ejh.13284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
8 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
9 Riley M, Der Mesropian P, Maheshwari A, Arslan ME, Visrodia P, Salman L, Peredo-Wende R, Foulke L, Hongalgi K. Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy. J Investig Med High Impact Case Rep 2022;10:23247096221074591. [PMID: 35152792 DOI: 10.1177/23247096221074591] [Reference Citation Analysis]
10 Lokki AI, Heikkinen-Eloranta JK, Laivuori H. The Immunogenetic Conundrum of Preeclampsia. Front Immunol 2018;9:2630. [PMID: 30483272 DOI: 10.3389/fimmu.2018.02630] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
11 Vaught AJ, Braunstein E, Chaturvedi S, Blakemore K, Brodsky RA. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med 2020;:1-9. [PMID: 32338085 DOI: 10.1080/14767058.2020.1755650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 González DP, Iglicki M, Svetitsky S, Bar-On Y, Habot-Wilner Z, Zur D. Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome - a case report. BMC Ophthalmol 2021;21:65. [PMID: 33516177 DOI: 10.1186/s12886-021-01820-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alhabhbeh A, Fatima Z, Thomas A, Cook C. Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult. Cureus 2021;13:e18184. [PMID: 34589371 DOI: 10.7759/cureus.18184] [Reference Citation Analysis]
15 Kollbrunner L, Hirt-Minkowski P, Sanz J, Bresin E, Neuhaus TJ, Hopfer H, Jehle AW. Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome. Front Med (Lausanne) 2021;8:679048. [PMID: 34150810 DOI: 10.3389/fmed.2021.679048] [Reference Citation Analysis]
16 Al-Shyoukh A, Younis M, Abughanimeh O, Tahboub M, Hamarshi MS. An Unusual Case of Diffuse Alveolar Hemorrhage as a Clinical Manifestation of Atypical Hemolytic Uremic Syndrome: A Case Report. Cureus 2019;11:e5059. [PMID: 31516771 DOI: 10.7759/cureus.5059] [Reference Citation Analysis]